Investing.com - Zimmer Biomet (NYSE: ZBH) reported second quarter EPS of $2.01, $0.02 better than the analyst estimate of $1.99. Revenue for the quarter came in at $1.94B versus the consensus estimate of $1.94B.
Guidance
Zimmer Biomet sees FY 2024 EPS of $8.00-$8.15 versus the analyst consensus of $8.09.
Zimmer Biomet's stock price closed at $109.57. It is down -9.68% in the last 3 months and down -12.25% in the last 12 months.
Zimmer Biomet saw 2 positive EPS revisions and 21 negative EPS revisions in the last 90 days. See Zimmer Biomet's stock price’s past reactions to earnings here.
According to InvestingPro, Zimmer Biomet's Financial Health score is "great performance".
Check out Zimmer Biomet's recent earnings performance, and Zimmer Biomet's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar